1 はじめに
1.1 調査目的 44
1.2 市場の定義 44
1.3 調査範囲
1.3.1 対象市場と地域範囲 45
1.3.2 対象範囲と除外範囲 46
1.3.3 考慮した年数 47
1.4 考慮した通貨 47
1.5 利害関係者 47
1.6 変更点のまとめ 48
2 調査方法 49
2.1 調査データ 49
2.1.1 二次データ 50
2.1.2 一次データ 50
2.2 市場推計方法 52
2.2.1 市場推計 52
2.2.2 一次専門家による洞察 54
2.2.3 トップダウンアプローチ 55
2.3 市場成長率の予測 56
2.4 市場の内訳とデータの三角測量 58
2.5 リサーチの前提 59
2.6 調査の限界 59
2.7 リスク分析 60
3 エグゼクティブサマリー
4 プレミアムインサイト 66
4.1 タンパク質発現市場の概要
4.2 北米：タンパク質発現市場：オファリング別、国別、2023年 67
4.3 タンパク質発現市場シェア、システムタイプ別、2024年対2029年 67
4.4 タンパク質発現製品市場：エンドユーザー別、2023年 68
4.5 タンパク質発現サービス市場：エンドユーザー別、2023年 68
4.6 タンパク質発現市場：国別 69
5 市場の概要
5.1 はじめに
5.2 市場ダイナミクス
5.2.1 推進要因
5.2.1.1 生物製剤の需要増加 71
5.2.1.2 製薬・バイオ医薬品業界における研究開発の増加 74
5.2.1.3 人工知能と機械学習の利用の増加 74
5.2.1.4 個別化医薬品へのシフトの増加 75
5.2.1.5 臨床活動のアウトソーシングの増加 76
5.2.2 阻害要因 77
5.2.2.1 タンパク質発現提供の高コスト 77
77 5.2.2.2 医薬品開発における低分子への再注目 77
5.2.3 機会 78
5.2.3.1 植物由来および無細胞発現系への注目の高まり 78
5.2.3.2 新興国における市場の活況 78
5.2.3.3 合成タンパク質生産技術の開発の増加 79
5.2.3.4 組換えタンパク質の利用拡大 80
5.2.4 課題 80
5.2.4.1 生産コストと効率の問題 80
5.3 顧客ビジネスに影響を与えるトレンド／混乱 81
5.4 価格分析 82
5.4.1 タンパク質発現製品の平均販売価格動向 82
5.4.2 主要プレーヤー別の平均販売価格 83
5.4.2.1 システムタイプの平均販売価格（主要プレーヤー別） 83
5.4.2.2 タンパク質発現装置の平均販売価格動向、
主要プレーヤー別 85
5.4.3 平均販売価格（地域別） 86
5.4.3.1 タンパク質発現消耗品の平均販売価格（地域別） 86
地域別 86
5.4.3.2 タンパク質発現装置の平均販売価格動向、
地域別 88
5.5 サプライチェーン分析 89
5.6 バリューチェーン分析 90
5.7 エコシステム分析 93
5.8 投資／資金調達活動 95
5.9 技術分析 96
5.9.1 主要技術 96
5.9.1.1 組換えDNA技術 96
5.9.1.2 トランスフェクション技術 96
5.9.1.2.1 試薬ベースのトランスフェクション 96
5.9.1.2.2 装置ベースのトランスフェクション 97
5.9.1.2.3 ウイルスベースのトランスフェクション 98
5.9.1.3 タンパク質発現システム 98
5.9.1.3.1 細菌発現システム 99
5.9.1.3.2 哺乳動物発現系 99
5.9.1.3.3 酵母発現系 99
5.9.1.3.4 昆虫発現系 99
5.9.1.3.5 無細胞発現系 99
5.9.2 隣接技術 100
5.9.2.1 抽出技術 100
5.9.2.1.1 非機械的方法 100
5.9.2.1.2 機械的方法 101
5.9.2.2 精製及び特性評価技術 101
5.9.2.2.1 タンパク質精製技術 101
5.9.2.2.2 タンパク質特性解析技術 101
5.9.3 補完的技術 102
5.9.3.1 ハイスループット技術 102
5.9.3.2 計算タンパク質設計 102
5.10 特許分析 103
5.11 貿易分析 106
5.11.1 輸入データ 106
5.11.2 輸出データ 108
5.12 主要会議・イベント（2024-2025年） 109
5.13 規制分析 110
5.13.1 規制情勢 110
5.13.1.1 北米 110
5.13.1.2 欧州 110
5.13.1.3 新興国 111
5.13.2 規制機関、政府機関、その他の団体 111
5.14 ポーターの5つの力分析 115
5.14.1 競争相手の強さ 116
5.14.2 サプライヤーの交渉力 116
5.14.3 買い手の交渉力 116
5.14.4 新規参入の脅威 116
5.14.5 代替品の脅威 117
5.15 主要ステークホルダーと購買基準 117
5.15.1 購入プロセスにおける主要ステークホルダー 117
5.15.2 購入基準 118
5.15.2.1 タンパク質発現製品の購入基準 118
5.15.2.2 タンパク質発現サービスの購入基準 120
5.16 AI／遺伝子AIがタンパク質発現市場に与える影響 121
5.16.1 導入 121
5.16.2 タンパク質発現アプリケーションの市場ポテンシャル 121
5.16.3 AIの使用例 122
5.16.4 AIを導入する主要企業 123
5.16.5 タンパク質発現エコシステムにおけるジェネレーティブAIの将来性 123
6 タンパク質発現市場：製品別 124
6.1 はじめに 125
6.2 製品 125
6.2.1 試薬・キット 128
6.2.1.1 増え続けるクローニング、トランスフェクション、精製、特性解析への使用 128
6.2.2 発現ベクター 131
6.2.2.1 複雑なタンパク質の生産の増加が市場を促進 131
6.2.3 コンピテントセル 133
6.2.3.1 治療用タンパク質への需要の増加が成長を促進 133
6.2.4 機器・ソフトウェア 136
6.2.4.1 バイオ医薬品と個別化治療の需要増加が成長を促進 136
6.3 サービス 138
6.3.1 大規模生産におけるタンパク質発現サービスの利用拡大が市場を後押し 138
7 タンパク質発現市場：システムタイプ別 141
7.1 はじめに 142
7.2 哺乳動物細胞発現システム 142
7.2.1 中国ハムスター卵巣（cho）細胞システム 146
7.2.1.1 高い生存率、急速な成長、成長を支える発現レベルの向上 146
7.2.2 ヒト胚性腎臓（hek 293）細胞システム 148
7.2.2.1 成長を増強するための一過性トランスフェクション研究における広範な使用 148
7.2.3 その他の哺乳動物細胞系 151
7.3 原核生物発現系 154
7.3.1 大腸菌システム 157
7.3.1.1 細胞密度が高く、増殖を刺激する培地のコストが低い 157
7.3.2 その他の原核生物発現系 159
7.4 昆虫細胞発現系 162
7.4.1 バキュロウイルス系 165
7.4.1.1 生物学的に活性で機能的な組換えタンパク質の増産による成長の加速 165
7.4.2 その他の昆虫細胞発現システム 167
7.5 酵母発現システム 170
7.5.1 Pichiaシステム 173
7.5.1.1 抗体断片やワクチン生産の増加が成長を促進 173
7.5.2 サッカロミセス・システム 175
7.5.2.1 異種タンパク質を生産するためのサッカロミセス系の利用が増加し、成長を加速 175
7.5.3 その他の酵母発現系 178
7.6 無細胞発現系 180
7.6.1 組換えタンパク質に対する需要の増加が市場を支える 180
7.7 藻類ベースの発現システム 183
7.7.1 抗体やワクチン作製における藻類ベースの発現システムの利用拡大が市場を後押し 183
8 タンパク質発現市場：ワークフロー別 186
8.1 導入 187
8.2 クローニングとトランスフェクション 187
8.2.1 消耗品と試薬の継続的補充が市場を支える 187
8.3 転写、翻訳、翻訳後修飾（ptm） 190
8.3.1 機能的で安定したタンパク質へのニーズの高まりが市場を牽引 190
8.4 抽出、精製、特性評価 192
8.4.1 適切な用途に必要な標準を遵守する必要性が市場を牽引 192
9 タンパク質発現市場、用途別 195
9.1 導入 196
9.2 治療用途 196
9.2.1 生物製剤治療に対する需要の高まりが成長を促進 196
9.3 研究用途
9.3.1 プロテオミクス、ゲノミクス、創薬への関心の高まりが市場を押し上げる 199
9.4 産業用途 202
9.4.1 化粧品、繊維製品、工業用酵素におけるタンパク質利用の増加が成長を促進する 202
10 タンパク質発現製品市場（エンドユーザー別） 206
10.1 導入 207
10.2 製薬・バイオテクノロジー企業 207
10.2.1 生物製剤の承認増加による成長促進 207
10.3 学術・研究機関 210
10.3.1 政府と民間からの資金提供の増加が市場成長に寄与 210
10.4 医薬品開発・製造受託機関（CRO・CDM） 213
10.4.1 医薬品製造と臨床試験におけるアウトソーシングと提携の増加が市場を維持 213
10.5 その他のエンドユーザー 217
11 タンパク質発現サービス市場：エンドユーザー別 220
11.1 はじめに 221
11.2 製薬・バイオテクノロジー企業 221
11.2.1 医薬品開発のアウトソーシングへのシフトが成長を後押し 221
11.3 学術・研究機関 224
224 11.3.1 学術機関と受託研究機関とのパートナーシップの増加が成長を後押し 224
11.4 その他のエンドユーザー 227
12 タンパク質発現市場：地域別 230
12.1 はじめに 231
12.2 北米 231
12.2.1 北米のマクロ経済見通し 237
12.2.2 米国 237
12.2.2.1 新規治療薬とタンパク質ベースの医薬品開発への注目の高まりが市場を牽引 237
12.2.3 カナダ 242
12.2.3.1 癌罹患率の増加と官民パートナーシップの普及が成長を持続 242
12.3 欧州 246
12.3.1 欧州のマクロ経済見通し 251
12.3.2 ドイツ 252
12.3.2.1 プロテオミクスに基づく研究と医療投資の増加が成長を促進 252
12.3.3 英国 256
12.3.3.1 免疫療法、ワクチン、プロテオミクスの開発が市場を活性化 256
12.3.4 フランス 260
12.3.4.1 プロテオミクスとゲノミクスへの資金提供の増加が成長を促進 260
12.3.5 イタリア 265
12.3.5.1 大学や研究機関が支援するライフサイエンス研究の成長が市場を後押し 265
12.3.6 スペイン 269
12.3.6.1 医薬品開発のための国際共同研究の増加が市場を活性化 269
12.3.7 オランダ 273
12.3.7.1 先進的なインフラの存在が市場を後押し 273
12.3.8 その他の欧州 277
12.4 アジア太平洋地域 281
12.4.1 アジア太平洋地域のマクロ経済見通し 287
12.4.2 中国 288
288 12.4.2.1 ゲノム・タンパク質研究への政府資金投入が市場を押し上げる 288
12.4.3 日本 292
12.4.3.1 ライフサイエンス分野における政府団体によるイニシアチブの増加が市場成長を後押し 292
12.4.4 インド 297
297 12.4.4.1 民間セクターと学界の協力関係の高まりが成長を促進 297
12.4.5 オーストラリア 301
12.4.5.1 新規タンパク質・ペプチド開発への注目の高まりが市場を牽引 301
12.4.6 韓国 305
12.4.6.1 新規治療法の研究開発の増加が成長を促進 305
12.4.7 その他のアジア太平洋地域 310
12.5 ラテンアメリカ 314
12.5.1 ラテンアメリカのマクロ経済見通し 319
12.5.2 ブラジル 320
12.5.2.1 産業投資の拡大が市場を牽引 320
12.5.3 メキシコ 324
12.5.3.1 慢性疾患の増加と強固な研究エコシステムが成長を促進 324
12.5.4 アルゼンチン 328
12.5.4.1 バイオテクノロジーと医薬品研究開発の増加が成長を促進 328
12.5.5 その他のラテンアメリカ 332
12.6 中東 336
12.6.1 中東のマクロ経済見通し 341
12.6.2 GCC諸国 342
12.6.2.1 政府当局と民間プレイヤー間の戦略的投資が市場を牽引 342
12.6.3 その他の中東地域 346
12.7 アフリカ 350
12.7.1 有利な保険制度と臨床試験が市場成長に寄与 350
12.7.2 アフリカのマクロ経済見通し 354
13 競争環境 356
13.1 概要 356
13.2 主要プレーヤーの戦略／勝利への権利（2021～2024年） 356
13.3 収益分析、2021～2023年 359
13.4 市場シェア分析、2023年 360
13.5 企業評価象限：主要プレーヤー、2023年 363
13.5.1 スター企業 363
13.5.2 新興リーダー 363
13.5.3 浸透型プレーヤー 363
13.5.4 参加企業 363
13.5.5 企業フットプリント：主要プレーヤー（2023年） 365
13.5.5.1 企業フットプリント 365
13.5.5.2 地域別フットプリント 366
13.5.5.3 オファリングのフットプリント 367
13.5.5.4 表現システムのフットプリント 369
13.5.5.5 アプリケーション・フットプリント 361
13.6 企業評価マトリックス：新興企業／SM（2023年） 372
13.6.1 進歩的企業 372
13.6.2 反応性の高い企業 372
13.6.3 ダイナミックな企業 372
13.6.4 スタートアップ・ブロック 372
13.6.5 競争ベンチマーキング：新興企業／SM（2023年） 374
13.6.5.1 主要新興企業／SMESの詳細リスト 374
13.6.5.2 新興企業/SMEの競合ベンチマーキング 375
13.7 企業評価と財務指標 376
13.7.1 企業評価 376
13.7.2 財務指標 376
13.8 ブランド／製品の比較 377
13.9 競争シナリオ 378
13.9.1 製品／サービスの発売 378
13.9.2 取引 379
13.9.3 拡張 380
14 会社プロファイル 382
Thermo Fisher Scientific Inc. (US)
Merck KGaA (Germany)
Danaher Corporation (US)
Agilent Technologies Inc. (US)
Sartorius AG (Germany)
GenScript (US)
Takara Bio Inc. (Japan)
Lonza (Switzerland)
15 付録 463
15.1 ディスカッションガイド 463
15.2 Knowledgestore： Marketsandmarketsの購読ポータル 467
15.3 カスタマイズオプション 469
15.4 関連レポート 469
15.5 著者の詳細 470
Factors such as the increasing demand for biologics supported by the rise in R&D activities in the pharmaceutical and biopharmaceutical industry and the growing use of artificial intelligence and machine learning to enhance protein-based studies are supporting the growth of the market. Moreover, factors such as the ongoing shift toward the development of personalized medicines, the rise in outsourcing services for clinical activities, the growing emphasis on the use of plant-based and cell-free expression systems, and the development of synthetic protein production technologies provide growth opportunities for players within the protein expression market. However, the high cost of protein expression reagents and instruments and the challenges associated with various expression systems are expected to restrain the growth of this market.
“The product segment registered the highest growth rate in the protein expression market, by offerings, during the forecast period”
In 2023, the products segment registered the highest growth rate within the protein expression market by offerings. Factors such as the rise in protein-based research and increasing approvals and commercialization of biologics, such as antibodies and vaccines are supporting the high growth of this segment. The products segment includes various reagents & kits, expression vectors, competent cells, and instruments that aid during various phases of protein expression. Reagents & kits accounted for the largest segment of the protein expression products market due to the continuous demand for these products during the protein expression workflow. Advancements in protein expression technologies and the launch of new and efficient reagents and kits are also supporting the growth of this product segment. Additionally, the rising focus on personalized medicine and biologics, such as antibodies and vaccines, is creating more demand for these products.
“The academic research institutes registered the highest growth rate in the protein expression services market, by end user, during the forecast period”
The academic research institute end user segment registered the highest growth rate within the protein expression services market by end user during the forecast period. Factors such as the increasing demand for innovative research solutions for biological and biomedical research supported by an increase in funding and grants from governments and pharmaceutical companies are supporting the high growth of this end user segment. Moreover, there is an increase in the number of collaborations between research institutes and pharmaceutical companies for the development of protein-based therapies such as antibodies and vaccines for the treatment of various chronic illnesses. This high growth is projected to continue during the forecast period.
“North America: The largest and fastest-growing region in the Protein Expression market”
The protein expression market in North America is projected to register the highest growth rate during the forecast period. This high growth is attributed to the presence of an established biotechnology and pharmaceuticals sector focusing on the development of protein-based therapies leading to a high demand for protein expression products and services. The region has key protein expression products and services suppliers and end-users as well as advanced research facilities and large R&D expenditures. In addition, the rise of chronic conditions such as cancer and diabetes has also supported the need for new protein-based drugs, increasing the demand for efficient protein expression technologies. In addition, the support and funding from the government for life sciences research also support the large market share of North America in the global protein expression market.
The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 – 32%, Tier 2 – 44%, and Tier 3 – 24%
• By Designation: (Managers) - 45%, (CXOs, Directors)- 30%, and(Executives) - 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -5%, Middle East- 5%, Africa-5%
List of Companies Profiled in the Report:
• Thermo Fisher Scientific, Inc. (US)
• Merck KGaA (Germany)
• GenScript (US)
• Agilent Technologies, Inc. (US)
• Takara Bio Inc. (Japan)
• Lonza (Switzerland)
• Promega Corporation (US)
• OriGene Technologies, Inc. (US)
• Qiagen (Netherlands)
• Bio-Rad Laboratories, Inc. (US)
• Danaher Corporation (US)
• Sartorius AG (Germany)
• FUJIFILM Irvine Scientific, Inc. (Japan)
• Bioneer Corporation (South Korea)
• LGC Limited (UK)
• Sino Biological, Inc. (China)
• New England BioLabs (US)
• LifeSensors Inc. (US)
• Jena Bioscience GmbH (Germany)
• Charles River Laboratories (US)
• Corning Incorporated (US)
• Eurofins Scientific (Luxembourg)
• Ajinomoto Co., Inc. (Ajinomoto Bio-Pharma Services) (Japan)
• Syngene International Limited (India)
• Aragen Life Sciences Ltd. (India)
Research Coverage:
This report provides a detailed picture of the global Protein Expression Market. It aims at estimating the size and future growth potential of the market across different segments such as the system type, offerings, workflow, application, products end user, services end user, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the protein expression market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the protein expression market. Competitive analysis of upcoming startups in the protein expression market ecosystem is covered in this report.
Reasons to buy this report :
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall protein expression market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
•Analysis of key drivers (Increasing demand for biologics, Rise in R&D in pharmaceutical and biopharmaceutical industries, Growing use of artificial intelligence and machine learning, Increasing shift toward personalized medicines, and Growing outsourcing of clinical activities), restraints (High cost of protein expression offerings and the dominance of small molecules in drug development), opportunities (Growing emphasis on plant-based and cell-free expression systems, Booming markets in emerging economies, Increasing development of new synthetic protein production technologies, and Growing use of recombinant proteins), and challenges (Production cost and efficiency issues) influencing the growth of the protein expression market.
•Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the protein expression market
•Market Development: Comprehensive information about lucrative markets – the report analyses the protein expression market across varied regions.
•Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the protein expression market
•Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Agilent Technologies, Inc. (US), Sartorius AG (Germany), GenScript (US), Takara Bio Inc. (Japan), Lonza (Switzerland), among others in protein expression market.
1 INTRODUCTION 44
1.1 STUDY OBJECTIVES 44
1.2 MARKET DEFINITION 44
1.3 STUDY SCOPE 45
1.3.1 MARKETS COVERED AND REGIONAL SCOPE 45
1.3.2 INCLUSIONS AND EXCLUSIONS 46
1.3.3 YEARS CONSIDERED 47
1.4 CURRENCY CONSIDERED 47
1.5 STAKEHOLDERS 47
1.6 SUMMARY OF CHANGES 48
2 RESEARCH METHODOLOGY 49
2.1 RESEARCH DATA 49
2.1.1 SECONDARY DATA 50
2.1.2 PRIMARY DATA 50
2.2 MARKET ESTIMATION METHODOLOGY 52
2.2.1 MARKET ESTIMATION 52
2.2.2 INSIGHTS FROM PRIMARY EXPERTS 54
2.2.3 TOP-DOWN APPROACH 55
2.3 MARKET GROWTH RATE PROJECTIONS 56
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 58
2.5 RESEARCH ASSUMPTIONS 59
2.6 RESEARCH LIMITATIONS 59
2.7 RISK ANALYSIS 60
3 EXECUTIVE SUMMARY 61
4 PREMIUM INSIGHTS 66
4.1 PROTEIN EXPRESSION MARKET OVERVIEW 66
4.2 NORTH AMERICA: PROTEIN EXPRESSION MARKET, BY OFFERING AND COUNTRY, 2023 67
4.3 PROTEIN EXPRESSION MARKET SHARE, BY SYSTEM TYPE, 2024 VS. 2029 67
4.4 PROTEIN EXPRESSION PRODUCTS MARKET, BY END USER, 2023 68
4.5 PROTEIN EXPRESSION SERVICES MARKET, BY END USER, 2023 68
4.6 PROTEIN EXPRESSION MARKET, BY COUNTRY 69
5 MARKET OVERVIEW 70
5.1 INTRODUCTION 70
5.2 MARKET DYNAMICS 70
5.2.1 DRIVERS 71
5.2.1.1 Increasing demand for biologics 71
5.2.1.2 Rise in R&D in pharmaceutical and biopharmaceutical industries 74
5.2.1.3 Growing use of artificial intelligence and machine learning 74
5.2.1.4 Increasing shift toward personalized medicines 75
5.2.1.5 Growing outsourcing of clinical activities 76
5.2.2 RESTRAINTS 77
5.2.2.1 High cost of protein expression offerings 77
5.2.2.2 Renewed focus on small molecules in drug development 77
5.2.3 OPPORTUNITIES 78
5.2.3.1 Growing emphasis on plant-based and cell-free expression systems 78
5.2.3.2 Booming market in emerging economies 78
5.2.3.3 Increasing development of synthetic protein production technologies 79
5.2.3.4 Growing use of recombinant proteins 80
5.2.4 CHALLENGES 80
5.2.4.1 Production cost and efficiency issues 80
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 81
5.4 PRICING ANALYSIS 82
5.4.1 AVERAGE SELLING PRICE TREND OF PROTEIN EXPRESSION PRODUCTS 82
5.4.2 AVERAGE SELLING PRICE, BY KEY PLAYER 83
5.4.2.1 Average selling price of system types, by key player 83
5.4.2.2 Average selling price trend of protein expression instruments,
by key player 85
5.4.3 AVERAGE SELLING PRICE, BY REGION 86
5.4.3.1 Average selling price of protein expression consumable products,
by region 86
5.4.3.2 Average selling price trend of protein expression instruments,
by region 88
5.5 SUPPLY CHAIN ANALYSIS 89
5.6 VALUE CHAIN ANALYSIS 90
5.7 ECOSYSTEM ANALYSIS 93
5.8 INVESTMENT/FUNDING ACTIVITY 95
5.9 TECHNOLOGY ANALYSIS 96
5.9.1 KEY TECHNOLOGIES 96
5.9.1.1 Recombinant DNA technology 96
5.9.1.2 Transfection technologies 96
5.9.1.2.1 Reagent-based transfection 96
5.9.1.2.2 Instrument-based transfection 97
5.9.1.2.3 Virus-based transfection 98
5.9.1.3 Protein expression systems 98
5.9.1.3.1 Bacterial expression systems 99
5.9.1.3.2 Mammalian expression systems 99
5.9.1.3.3 Yeast expression systems 99
5.9.1.3.4 Insect expression systems 99
5.9.1.3.5 Cell-free expression systems 99
5.9.2 ADJACENT TECHNOLOGIES 100
5.9.2.1 Extraction technologies 100
5.9.2.1.1 Non-mechanical methods 100
5.9.2.1.2 Mechanical methods 101
5.9.2.2 Purification and characterization technologies 101
5.9.2.2.1 Protein purification technologies 101
5.9.2.2.2 Protein characterization technologies 101
5.9.3 COMPLEMENTARY TECHNOLOGIES 102
5.9.3.1 High-throughput technologies 102
5.9.3.2 Computation protein designing 102
5.10 PATENT ANALYSIS 103
5.11 TRADE ANALYSIS 106
5.11.1 IMPORT DATA 106
5.11.2 EXPORT DATA 108
5.12 KEY CONFERENCES AND EVENTS, 2024–2025 109
5.13 REGULATORY ANALYSIS 110
5.13.1 REGULATORY LANDSCAPE 110
5.13.1.1 North America 110
5.13.1.2 Europe 110
5.13.1.3 Emerging economies 111
5.13.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 111
5.14 PORTER’S FIVE FORCES ANALYSIS 115
5.14.1 INTENSITY OF COMPETITIVE RIVALRY 116
5.14.2 BARGAINING POWER OF SUPPLIERS 116
5.14.3 BARGAINING POWER OF BUYERS 116
5.14.4 THREAT OF NEW ENTRANTS 116
5.14.5 THREAT OF SUBSTITUTES 117
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 117
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 117
5.15.2 BUYING CRITERIA 118
5.15.2.1 Buying criteria for protein expression products 118
5.15.2.2 Buying criteria for protein expression services 120
5.16 IMPACT OF AI/GEN AI ON PROTEIN EXPRESSION MARKET 121
5.16.1 INTRODUCTION 121
5.16.2 MARKET POTENTIAL FOR PROTEIN EXPRESSION APPLICATIONS 121
5.16.3 AI USE CASES 122
5.16.4 KEY COMPANIES IMPLEMENTING AI 123
5.16.5 FUTURE OF GENERATIVE AI IN PROTEIN EXPRESSION ECOSYSTEM 123
6 PROTEIN EXPRESSION MARKET, BY OFFERING 124
6.1 INTRODUCTION 125
6.2 PRODUCTS 125
6.2.1 REAGENTS & KITS 128
6.2.1.1 Increasing use for cloning, transfection, purification, and characterization to spur growth 128
6.2.2 EXPRESSION VECTORS 131
6.2.2.1 Growing production of complex proteins to propel market 131
6.2.3 COMPETENT CELLS 133
6.2.3.1 Increasing demand for therapeutic proteins to expedite growth 133
6.2.4 INSTRUMENTS & SOFTWARE 136
6.2.4.1 Increasing demand for biopharmaceuticals and personalized therapies to augment growth 136
6.3 SERVICES 138
6.3.1 GROWING UTILIZATION OF PROTEIN EXPRESSION SERVICES FOR LARGE-SCALE PRODUCTION TO FUEL MARKET 138
7 PROTEIN EXPRESSION MARKET, BY SYSTEM TYPE 141
7.1 INTRODUCTION 142
7.2 MAMMALIAN CELL EXPRESSION SYSTEMS 142
7.2.1 CHINESE HAMSTER OVARY (CHO) CELL SYSTEMS 146
7.2.1.1 High viability, rapid growth, and improved expression levels to support growth 146
7.2.2 HUMAN EMBRYONIC KIDNEY (HEK 293) CELL SYSTEMS 148
7.2.2.1 Wide usage in transient transfection studies to augment growth 148
7.2.3 OTHER MAMMALIAN CELL SYSTEMS 151
7.3 PROKARYOTIC EXPRESSION SYSTEMS 154
7.3.1 ESCHERICHIA COLI SYSTEMS 157
7.3.1.1 High cell density and low cost of media to stimulate growth 157
7.3.2 OTHER PROKARYOTIC EXPRESSION SYSTEMS 159
7.4 INSECT CELL EXPRESSION SYSTEMS 162
7.4.1 BACULOVIRUS SYSTEMS 165
7.4.1.1 Increasing production of biologically active and functional recombinant proteins to speed up growth 165
7.4.2 OTHER INSECT CELL EXPRESSION SYSTEMS 167
7.5 YEAST EXPRESSION SYSTEMS 170
7.5.1 PICHIA SYSTEMS 173
7.5.1.1 Rising production of antibody fragments, and vaccines to fuel growth 173
7.5.2 SACCHAROMYCES SYSTEMS 175
7.5.2.1 Increasing use of saccharomyces systems for producing heterologous proteins to accelerate growth 175
7.5.3 OTHER YEAST EXPRESSION SYSTEMS 178
7.6 CELL-FREE EXPRESSION SYSTEMS 180
7.6.1 INCREASING DEMAND FOR RECOMBINANT PROTEINS TO SUPPORT MARKET 180
7.7 ALGAL-BASED EXPRESSION SYSTEMS 183
7.7.1 GROWING USE OF ALGAL-BASED EXPRESSION SYSTEMS IN ANTIBODY AND VACCINE GENERATION TO BOOST MARKET 183
8 PROTEIN EXPRESSION MARKET, BY WORKFLOW 186
8.1 INTRODUCTION 187
8.2 CLONING & TRANSFECTION 187
8.2.1 CONTINUOUS REPLENISHMENT OF CONSUMABLES AND REAGENTS TO SUPPORT MARKET 187
8.3 TRANSCRIPTION, TRANSLATION, AND POST-TRANSLATIONAL MODIFICATION (PTM) 190
8.3.1 GROWING NEED FOR FUNCTIONAL AND STABLE PROTEINS TO DRIVE MARKET 190
8.4 EXTRACTION, PURIFICATION, AND CHARACTERIZATION 192
8.4.1 NEED TO ADHERE TO REQUIRED STANDARDS FOR SUITABLE APPLICATIONS TO DRIVE MARKET 192
9 PROTEIN EXPRESSION MARKET, BY APPLICATION 195
9.1 INTRODUCTION 196
9.2 THERAPEUTIC APPLICATIONS 196
9.2.1 RISING DEMAND FOR BIOLOGICS THERAPIES TO FACILITATE GROWTH 196
9.3 RESEARCH APPLICATIONS 199
9.3.1 GROWING INTEREST IN PROTEOMICS, GENOMICS, AND DRUG DISCOVERY TO BOOST MARKET 199
9.4 INDUSTRIAL APPLICATIONS 202
9.4.1 INCREASING USE OF PROTEINS IN COSMETICS, TEXTILES, AND INDUSTRIAL ENZYMES TO PROMOTE GROWTH 202
10 PROTEIN EXPRESSION PRODUCTS MARKET, BY END USER 206
10.1 INTRODUCTION 207
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 207
10.2.1 INCREASING APPROVALS FOR BIOLOGICS TO STIMULATE GROWTH 207
10.3 ACADEMIC & RESEARCH INSTITUTES 210
10.3.1 RISE IN GOVERNMENT AND PRIVATE FUNDING TO CONTRIBUTE TO MARKET GROWTH 210
10.4 CONTRACT RESEARCH ORGANIZATIONS & CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CROS & CDMOS) 213
10.4.1 INCREASING OUTSOURCING AND COLLABORATIONS FOR PHARMACEUTICAL MANUFACTURING AND CLINICAL TRIALS TO SUSTAIN MARKET 213
10.5 OTHER END USERS 217
11 PROTEIN EXPRESSION SERVICES MARKET, BY END USER 220
11.1 INTRODUCTION 221
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 221
11.2.1 INCREASING SHIFT TOWARD DRUG DEVELOPMENT OUTSOURCING TO FAVOR GROWTH 221
11.3 ACADEMIC & RESEARCH INSTITUTES 224
11.3.1 RISING PARTNERSHIPS BETWEEN ACADEMIA AND CONTRACT RESEARCH ORGANIZATIONS TO AID GROWTH 224
11.4 OTHER END USERS 227
12 PROTEIN EXPRESSION MARKET, BY REGION 230
12.1 INTRODUCTION 231
12.2 NORTH AMERICA 231
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 237
12.2.2 US 237
12.2.2.1 Growing focus on developing new therapeutics and protein-based drugs to drive market 237
12.2.3 CANADA 242
12.2.3.1 Increasing incidence of cancer and prevalence of public-private partnerships to sustain growth 242
12.3 EUROPE 246
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 251
12.3.2 GERMANY 252
12.3.2.1 Increasing proteomics-based research and healthcare investments to promote growth 252
12.3.3 UK 256
12.3.3.1 Growing development of immunotherapies, vaccines, and proteomics to fuel market 256
12.3.4 FRANCE 260
12.3.4.1 Rise in funding for proteomics and genomics to spur growth 260
12.3.5 ITALY 265
12.3.5.1 Growing life science research supported by universities and research institutions to boost market 265
12.3.6 SPAIN 269
12.3.6.1 Increasing international collaborations for drug development to fuel market 269
12.3.7 NETHERLANDS 273
12.3.7.1 Presence of advanced infrastructure to fuel market 273
12.3.8 REST OF EUROPE 277
12.4 ASIA PACIFIC 281
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 287
12.4.2 CHINA 288
12.4.2.1 Extensive government funding in genomics and protein research to boost market 288
12.4.3 JAPAN 292
12.4.3.1 Increasing initiatives by government associations in life sciences sector to support market growth 292
12.4.4 INDIA 297
12.4.4.1 Rising collaborations between private sector and academia to facilitate growth 297
12.4.5 AUSTRALIA 301
12.4.5.1 Growing focus on developing new proteins and peptides to drive market 301
12.4.6 SOUTH KOREA 305
12.4.6.1 Increasing research & development of novel therapies to facilitate growth 305
12.4.7 REST OF ASIA PACIFIC 310
12.5 LATIN AMERICA 314
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 319
12.5.2 BRAZIL 320
12.5.2.1 Growing industrial investments to propel market 320
12.5.3 MEXICO 324
12.5.3.1 Increase in chronic diseases and robust research ecosystem to expedite growth 324
12.5.4 ARGENTINA 328
12.5.4.1 Rise in biotechnology and pharmaceutical research & development to augment growth 328
12.5.5 REST OF LATIN AMERICA 332
12.6 MIDDLE EAST 336
12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 341
12.6.2 GCC COUNTRIES 342
12.6.2.1 Strategic investments between government authorities and private players to drive market 342
12.6.3 REST OF MIDDLE EAST 346
12.7 AFRICA 350
12.7.1 FAVORABLE INSURANCE PROGRAMS AND CLINICAL TRIALS TO CONTRIBUTE TO MARKET GROWTH 350
12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 354
13 COMPETITIVE LANDSCAPE 356
13.1 OVERVIEW 356
13.2 KEY PLAYER STRATEGY/RIGHT TO WIN, 2021–2024 356
13.3 REVENUE ANALYSIS, 2021–2023 359
13.4 MARKET SHARE ANALYSIS, 2023 360
13.5 COMPANY EVALUATION QUADRANT: KEY PLAYERS, 2023 363
13.5.1 STARS 363
13.5.2 EMERGING LEADERS 363
13.5.3 PERVASIVE PLAYERS 363
13.5.4 PARTICIPANTS 364
13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 365
13.5.5.1 Company footprint 365
13.5.5.2 Region footprint 366
13.5.5.3 Offering footprint 367
13.5.5.4 Expression system footprint 369
13.5.5.5 Application footprint 371
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 372
13.6.1 PROGRESSIVE COMPANIES 372
13.6.2 RESPONSIVE COMPANIES 372
13.6.3 DYNAMIC COMPANIES 372
13.6.4 STARTING BLOCKS 372
13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 374
13.6.5.1 Detailed list of key startups/SMES 374
13.6.5.2 Competitive benchmarking of startups/SMEs 375
13.7 COMPANY VALUATION AND FINANCIAL METRICS 376
13.7.1 COMPANY VALUATION 376
13.7.2 FINANCIAL METRICS 376
13.8 BRAND/PRODUCT COMPARISON 377
13.9 COMPETITIVE SCENARIO 378
13.9.1 PRODUCT/SERVICE LAUNCHES 378
13.9.2 DEALS 379
13.9.3 EXPANSIONS 380
14 COMPANY PROFILES 382
14.1 KEY PLAYERS 382
14.1.1 THERMO FISHER SCIENTIFIC INC. 382
14.1.1.1 Business overview 382
14.1.1.2 Products and services offered 383
14.1.1.3 Recent developments 388
14.1.1.3.1 Product/Service launches 388
14.1.1.3.2 Deals 389
14.1.1.3.3 Expansions 389
14.1.1.4 MnM view 390
14.1.1.4.1 Key strengths 390
14.1.1.4.2 Strategic choices 390
14.1.1.4.3 Weaknesses and competitive threats 391
14.1.2 MERCK KGAA 392
14.1.2.1 Business overview 392
14.1.2.2 Products and services offered 393
14.1.2.3 Recent developments 395
14.1.2.3.1 Deals 395
14.1.2.3.2 Expansions 396
14.1.2.4 MnM view 398
14.1.2.4.1 Key strengths 398
14.1.2.4.2 Strategic choices 398
14.1.2.4.3 Weaknesses and competitive threats 398
14.1.3 DANAHER CORPORATION 399
14.1.3.1 Business overview 399
14.1.3.2 Products and services offered 400
14.1.3.3 Recent developments 402
14.1.3.3.1 Product/Service launches 402
14.1.3.3.2 Deals 403
14.1.3.3.3 Expansions 403
14.1.3.4 MnM view 404
14.1.3.4.1 Key strengths 404
14.1.3.4.2 Strategic choices 404
14.1.3.4.3 Weaknesses and competitive threats 404
14.1.4 AGILENT TECHNOLOGIES, INC. 405
14.1.4.1 Business overview 405
14.1.4.2 Products and services offered 406
14.1.4.3 MnM view 409
14.1.4.3.1 Key strengths 409
14.1.4.3.2 Strategic choices 409
14.1.4.3.3 Weaknesses and competitive threats 409
14.1.5 SARTORIUS AG 410
14.1.5.1 Business overview 410
14.1.5.2 Products and services offered 411
14.1.5.3 Recent developments 412
14.1.5.3.1 Deals 412
14.1.5.3.2 Expansions 413
14.1.5.4 MnM view 414
14.1.5.4.1 Key strength 414
14.1.5.4.2 Strategic choices 414
14.1.5.4.3 Weaknesses and competitive threats 414
14.1.6 GENSCRIPT 415
14.1.6.1 Business overview 415
14.1.6.2 Products and services offered 416
14.1.6.3 Recent developments 417
14.1.6.3.1 Product/Service launches 417
14.1.6.4 MnM view 418
14.1.6.4.1 Key strengths 418
14.1.6.4.2 Strategic choices 418
14.1.6.4.3 Weaknesses and competitive threats 418
14.1.7 TAKARA BIO INC. 419
14.1.7.1 Business overview 419
14.1.7.2 Products and services offered 421
14.1.8 BIO-RAD LABORATORIES, INC. 423
14.1.8.1 Business overview 423
14.1.8.2 Products and services offered 424
14.1.9 QIAGEN 426
14.1.9.1 Business overview 426
14.1.9.2 Products and services offered 428
14.1.10 CHARLES RIVER LABORATORIES 429
14.1.10.1 Business overview 429
14.1.10.2 Products and services offered 431
14.1.11 CORNING INCORPORATED 432
14.1.11.1 Business overview 432
14.1.11.2 Products and services offered 433
14.1.12 LONZA 435
14.1.12.1 Business overview 435
14.1.12.2 Products and services offered 436
14.1.12.3 Recent developments 438
14.1.12.3.1 Product/Service launches 438
14.1.12.3.2 Deals 438
14.1.13 FUJIFILM IRVINE SCIENTIFIC, INC. 439
14.1.13.1 Business overview 439
14.1.13.2 Products and services offered 440
14.1.13.3 Recent developments 442
14.1.13.3.1 Product/Service launches 442
14.1.13.3.2 Deals 442
14.1.13.3.3 Expansions 443
14.1.14 SYNGENE INTERNATIONAL LIMITED 444
14.1.14.1 Business overview 444
14.1.14.2 Products and services offered 445
14.1.14.3 Recent developments 445
14.1.14.3.1 Product/Service launches 445
14.1.15 LGC LIMITED 446
14.1.15.1 Business overview 446
14.1.15.2 Products and services offered 447
14.1.16 EUROFINS SCIENTIFIC 448
14.1.16.1 Business overview 448
14.1.16.2 Products and services offered 449
14.1.17 AJINOMOTO CO., INC. 450
14.1.17.1 Business overview 450
14.1.17.2 Products and services offered 451
14.2 OTHER PLAYERS 452
14.2.1 PROMEGA CORPORATION 452
14.2.2 SINO BIOLOGICAL, INC. 453
14.2.3 RAYBIOTECH, INC. 454
14.2.4 BIONEER CORPORATION 455
14.2.5 ORIGENE TECHNOLOGIES, INC. 456
14.2.6 NEW ENGLAND BIOLABS 457
14.2.7 ACCURUS BIOSCIENCES 458
14.2.8 ARAGEN LIFE SCIENCES LTD. 459
14.2.9 OXFORD EXPRESSION TECHNOLOGIES LTD 460
14.2.10 PROTEOGENIX INC. 461
14.2.11 ABEOMICS 462
15 APPENDIX 463
15.1 DISCUSSION GUIDE 463
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 467
15.3 CUSTOMIZATION OPTIONS 469
15.4 RELATED REPORTS 469
15.5 AUTHOR DETAILS 470
❖ 世界のタンパク質発現市場に関するよくある質問(FAQ) ❖
・タンパク質発現の世界市場規模は？
→MarketsandMarkets社は2024年のタンパク質発現の世界市場規模を34.1億米ドルと推定しています。
・タンパク質発現の世界市場予測は？
→MarketsandMarkets社は2029年のタンパク質発現の世界市場規模を48.2億米ドルと予測しています。
・タンパク質発現市場の成長率は？
→MarketsandMarkets社はタンパク質発現の世界市場が2024年～2029年に年平均7.1%成長すると予測しています。
・世界のタンパク質発現市場における主要企業は？
→MarketsandMarkets社は「Thermo Fisher Scientific Inc. (US)、Merck KGaA (Germany)、Danaher Corporation (US)、Agilent Technologies、Inc. (US)、Sartorius AG (Germany)、 GenScript (US)、Takara Bio Inc. (Japan)、Lonza (Switzerland)など ...」をグローバルタンパク質発現市場の主要企業として認識しています。
※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、納品レポートの情報と少し異なる場合があります。
